Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection
Very little longitudinal information is available regarding the performance of T cell-based tests for Mycobacterium tuberculosis infection. To address this deficiency, we conducted a longitudinal assessment of the enzyme-linked immunosorbent spot test (ELISPOT) test in comparison to the standard tub...
Gespeichert in:
| Veröffentlicht in: | PLoS medicine 2007-06, Vol.4 (6), p.e192-e192 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | e192 |
|---|---|
| container_issue | 6 |
| container_start_page | e192 |
| container_title | PLoS medicine |
| container_volume | 4 |
| creator | Hill, Philip C Brookes, Roger H Fox, Annette Jackson-Sillah, Dolly Jeffries, David J Lugos, Moses D Donkor, Simon A Adetifa, Ifedayo M de Jong, Bouke C Aiken, Alex M Adegbola, Richard A McAdam, Keith P |
| description | Very little longitudinal information is available regarding the performance of T cell-based tests for Mycobacterium tuberculosis infection. To address this deficiency, we conducted a longitudinal assessment of the enzyme-linked immunosorbent spot test (ELISPOT) test in comparison to the standard tuberculin skin test (TST).
In tuberculosis (TB) contacts we repeated ELISPOT tests 3 mo (n = 341) and 18 mo (n = 210) after recruitment and TSTs at 18 mo (n = 130). We evaluated factors for association with conversion and reversion and investigated suspected cases of TB. Of 207 ELISPOT-negative contacts, 51 (24.6%) had 3-mo ELISPOT conversion, which was associated with a positive recruitment TST (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.0-5.0, p = 0.048) and negatively associated with bacillus Calmette-Guérin (BCG) vaccination (OR 0.5, 95% CI 0.2-1.0, p = 0.06). Of 134 contacts, 54 (40.2%) underwent 3-mo ELISPOT reversion, which was less likely in those with a positive recruitment TST (OR 0.3, 95% CI 0.1-0.8, p = 0.014). Between 3 and 18 mo, 35/132 (26.5%) contacts underwent ELISPOT conversion and 28/78 (35.9%) underwent ELISPOT reversion. Of the 210 contacts with complete results, 73 (34.8%) were ELISPOT negative at all three time points; 36 (17.1%) were positive at all three time points. Between recruitment and 18 mo, 20 (27%) contacts had ELISPOT conversion; 37 (50%) had TST conversion, which was associated with a positive recruitment ELISPOT (OR 7.2, 95% CI 1.4-37.1, p = 0.019); 18 (32.7%) underwent ELISPOT reversion; and five (8.9%) underwent TST reversion. Results in 13 contacts diagnosed as having TB were mixed, but suggested higher TST sensitivity.
Both ELISPOT conversion and reversion occur after M. tuberculosis exposure. Rapid ELISPOT reversion may reflect M. tuberculosis clearance or transition into dormancy and may contribute to the relatively low reported ELISPOT conversion rate. Therefore, a negative ELISPOT test for M. tuberculosis infection should be interpreted with caution. |
| doi_str_mv | 10.1371/journal.pmed.0040192 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_plos_</sourceid><recordid>TN_cdi_plos_journals_1288097858</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A166988716</galeid><doaj_id>oai_doaj_org_article_7bf66ab6438d4702bb4500652f062723</doaj_id><sourcerecordid>A166988716</sourcerecordid><originalsourceid>FETCH-LOGICAL-c734t-d3efa05972b5940ab7ddc2415db81643cba63a44d51e3e221ce91351f90aa6833</originalsourceid><addsrcrecordid>eNqVk1-L1DAUxYso7rr6DUQLwoIPMyZp_vVFWJZVB0ZHnNXXkKRpJ0PbjEkq7rc341SdyjwofWhJfvecm5PeLHsKwRwWDL7ausH3sp3vOlPNAcAAluhedg4JLmeQMnr_6PssexTCFgBUghI8zM4gIxRjzs6z9dL1jY1DZZNWLkMwIXSmj7mrc9nnN8vF-uPqNo8mxLx2Pn9_p52SOhpvhy6PgzJeD60LNuS2r42O1vWPswe1bIN5Mr4vss9vbm6v382Wq7eL66vlTLMCx1lVmFoCUjKkSImBVKyqNMKQVIpDigutJC0kxhWBpjAIQW1KWBBYl0BKyoviInt-0N2lBsSYRxAQcQ5KxglPxOJAVE5uxc7bTvo74aQVPxecb4T00erWCKZqSqVKvrzCDCClMAGAElQDihjau70e3QaVItcpJC_bieh0p7cb0bhvAvLUNmRJ4HIU8O7rkAIVnQ3atK3sjRuCoBwSkI6ZwBd_gafPNjtQjUztp_BdctWN6U0yd72pbVq-gpSWnDNIEz8_waenMp3VJwteTgoSE8332MghBLFYf_oP9sO_s6svU_byiN0Y2cZNcO2w_83CFMQHUHsXgjf174uBQOzn5VeGYj8vYpyXVPbs-FL_FI0DUvwA7ZgPMA</addsrcrecordid><sourcetype>Open Website</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1288097858</pqid></control><display><type>article</type><title>Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection</title><source>MEDLINE</source><source>DOAJ Directory of Open Access Journals</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central</source><source>Public Library of Science (PLoS)</source><creator>Hill, Philip C ; Brookes, Roger H ; Fox, Annette ; Jackson-Sillah, Dolly ; Jeffries, David J ; Lugos, Moses D ; Donkor, Simon A ; Adetifa, Ifedayo M ; de Jong, Bouke C ; Aiken, Alex M ; Adegbola, Richard A ; McAdam, Keith P</creator><creatorcontrib>Hill, Philip C ; Brookes, Roger H ; Fox, Annette ; Jackson-Sillah, Dolly ; Jeffries, David J ; Lugos, Moses D ; Donkor, Simon A ; Adetifa, Ifedayo M ; de Jong, Bouke C ; Aiken, Alex M ; Adegbola, Richard A ; McAdam, Keith P</creatorcontrib><description>Very little longitudinal information is available regarding the performance of T cell-based tests for Mycobacterium tuberculosis infection. To address this deficiency, we conducted a longitudinal assessment of the enzyme-linked immunosorbent spot test (ELISPOT) test in comparison to the standard tuberculin skin test (TST).
In tuberculosis (TB) contacts we repeated ELISPOT tests 3 mo (n = 341) and 18 mo (n = 210) after recruitment and TSTs at 18 mo (n = 130). We evaluated factors for association with conversion and reversion and investigated suspected cases of TB. Of 207 ELISPOT-negative contacts, 51 (24.6%) had 3-mo ELISPOT conversion, which was associated with a positive recruitment TST (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.0-5.0, p = 0.048) and negatively associated with bacillus Calmette-Guérin (BCG) vaccination (OR 0.5, 95% CI 0.2-1.0, p = 0.06). Of 134 contacts, 54 (40.2%) underwent 3-mo ELISPOT reversion, which was less likely in those with a positive recruitment TST (OR 0.3, 95% CI 0.1-0.8, p = 0.014). Between 3 and 18 mo, 35/132 (26.5%) contacts underwent ELISPOT conversion and 28/78 (35.9%) underwent ELISPOT reversion. Of the 210 contacts with complete results, 73 (34.8%) were ELISPOT negative at all three time points; 36 (17.1%) were positive at all three time points. Between recruitment and 18 mo, 20 (27%) contacts had ELISPOT conversion; 37 (50%) had TST conversion, which was associated with a positive recruitment ELISPOT (OR 7.2, 95% CI 1.4-37.1, p = 0.019); 18 (32.7%) underwent ELISPOT reversion; and five (8.9%) underwent TST reversion. Results in 13 contacts diagnosed as having TB were mixed, but suggested higher TST sensitivity.
Both ELISPOT conversion and reversion occur after M. tuberculosis exposure. Rapid ELISPOT reversion may reflect M. tuberculosis clearance or transition into dormancy and may contribute to the relatively low reported ELISPOT conversion rate. Therefore, a negative ELISPOT test for M. tuberculosis infection should be interpreted with caution.</description><identifier>ISSN: 1549-1676</identifier><identifier>ISSN: 1549-1277</identifier><identifier>EISSN: 1549-1676</identifier><identifier>DOI: 10.1371/journal.pmed.0040192</identifier><identifier>PMID: 17564487</identifier><language>eng</language><publisher>United States: Public Library of Science</publisher><subject>Adolescent ; Adult ; Aged ; Antigens, Bacterial - immunology ; Bacteria ; Bacterial infections ; Bacterial Proteins - immunology ; Cohort Studies ; Comparative analysis ; Confidence intervals ; Contact Tracing ; Databases, Factual ; DNA, Bacterial - genetics ; Enzyme-Linked Immunosorbent Assay ; Enzymes ; False Negative Reactions ; Female ; Follow-Up Studies ; Gambia - epidemiology ; Genetic aspects ; Humans ; Immune system ; Immunology ; Immunology and allergy ; Infections ; Infectious Diseases ; Interferon-gamma - analysis ; Male ; Medicine in Developing Countries ; Middle Aged ; Mycobacterium tuberculosis - immunology ; Mycobacterium tuberculosis - isolation & purification ; Predictive Value of Tests ; Public Health ; Public Health and Epidemiology ; Reproducibility of Results ; Respiratory Medicine ; Sensitivity and Specificity ; Skin ; Sputum - microbiology ; T-Lymphocytes - immunology ; T-Lymphocytes - metabolism ; Time Factors ; Tuberculin Test ; Tuberculosis ; Tuberculosis - diagnosis ; Tuberculosis - epidemiology ; Tuberculosis - immunology ; Tuberculosis - microbiology</subject><ispartof>PLoS medicine, 2007-06, Vol.4 (6), p.e192-e192</ispartof><rights>COPYRIGHT 2007 Public Library of Science</rights><rights>2007 Hill et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited: Hill PC, Brookes RH, Fox A, Jackson-Sillah D, Jeffries DJ, et al. (2007) Longitudinal Assessment of an ELISPOT Test for Mycobacterium tuberculosis Infection. PLoS Med 4(6): e192. doi:10.1371/journal.pmed.0040192</rights><rights>2007 Hill et al. 2007</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c734t-d3efa05972b5940ab7ddc2415db81643cba63a44d51e3e221ce91351f90aa6833</citedby><cites>FETCH-LOGICAL-c734t-d3efa05972b5940ab7ddc2415db81643cba63a44d51e3e221ce91351f90aa6833</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891317/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC1891317/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,723,776,780,860,881,2096,2915,23845,27901,27902,53766,53768,79342,79343</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17564487$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Hill, Philip C</creatorcontrib><creatorcontrib>Brookes, Roger H</creatorcontrib><creatorcontrib>Fox, Annette</creatorcontrib><creatorcontrib>Jackson-Sillah, Dolly</creatorcontrib><creatorcontrib>Jeffries, David J</creatorcontrib><creatorcontrib>Lugos, Moses D</creatorcontrib><creatorcontrib>Donkor, Simon A</creatorcontrib><creatorcontrib>Adetifa, Ifedayo M</creatorcontrib><creatorcontrib>de Jong, Bouke C</creatorcontrib><creatorcontrib>Aiken, Alex M</creatorcontrib><creatorcontrib>Adegbola, Richard A</creatorcontrib><creatorcontrib>McAdam, Keith P</creatorcontrib><title>Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection</title><title>PLoS medicine</title><addtitle>PLoS Med</addtitle><description>Very little longitudinal information is available regarding the performance of T cell-based tests for Mycobacterium tuberculosis infection. To address this deficiency, we conducted a longitudinal assessment of the enzyme-linked immunosorbent spot test (ELISPOT) test in comparison to the standard tuberculin skin test (TST).
In tuberculosis (TB) contacts we repeated ELISPOT tests 3 mo (n = 341) and 18 mo (n = 210) after recruitment and TSTs at 18 mo (n = 130). We evaluated factors for association with conversion and reversion and investigated suspected cases of TB. Of 207 ELISPOT-negative contacts, 51 (24.6%) had 3-mo ELISPOT conversion, which was associated with a positive recruitment TST (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.0-5.0, p = 0.048) and negatively associated with bacillus Calmette-Guérin (BCG) vaccination (OR 0.5, 95% CI 0.2-1.0, p = 0.06). Of 134 contacts, 54 (40.2%) underwent 3-mo ELISPOT reversion, which was less likely in those with a positive recruitment TST (OR 0.3, 95% CI 0.1-0.8, p = 0.014). Between 3 and 18 mo, 35/132 (26.5%) contacts underwent ELISPOT conversion and 28/78 (35.9%) underwent ELISPOT reversion. Of the 210 contacts with complete results, 73 (34.8%) were ELISPOT negative at all three time points; 36 (17.1%) were positive at all three time points. Between recruitment and 18 mo, 20 (27%) contacts had ELISPOT conversion; 37 (50%) had TST conversion, which was associated with a positive recruitment ELISPOT (OR 7.2, 95% CI 1.4-37.1, p = 0.019); 18 (32.7%) underwent ELISPOT reversion; and five (8.9%) underwent TST reversion. Results in 13 contacts diagnosed as having TB were mixed, but suggested higher TST sensitivity.
Both ELISPOT conversion and reversion occur after M. tuberculosis exposure. Rapid ELISPOT reversion may reflect M. tuberculosis clearance or transition into dormancy and may contribute to the relatively low reported ELISPOT conversion rate. Therefore, a negative ELISPOT test for M. tuberculosis infection should be interpreted with caution.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Aged</subject><subject>Antigens, Bacterial - immunology</subject><subject>Bacteria</subject><subject>Bacterial infections</subject><subject>Bacterial Proteins - immunology</subject><subject>Cohort Studies</subject><subject>Comparative analysis</subject><subject>Confidence intervals</subject><subject>Contact Tracing</subject><subject>Databases, Factual</subject><subject>DNA, Bacterial - genetics</subject><subject>Enzyme-Linked Immunosorbent Assay</subject><subject>Enzymes</subject><subject>False Negative Reactions</subject><subject>Female</subject><subject>Follow-Up Studies</subject><subject>Gambia - epidemiology</subject><subject>Genetic aspects</subject><subject>Humans</subject><subject>Immune system</subject><subject>Immunology</subject><subject>Immunology and allergy</subject><subject>Infections</subject><subject>Infectious Diseases</subject><subject>Interferon-gamma - analysis</subject><subject>Male</subject><subject>Medicine in Developing Countries</subject><subject>Middle Aged</subject><subject>Mycobacterium tuberculosis - immunology</subject><subject>Mycobacterium tuberculosis - isolation & purification</subject><subject>Predictive Value of Tests</subject><subject>Public Health</subject><subject>Public Health and Epidemiology</subject><subject>Reproducibility of Results</subject><subject>Respiratory Medicine</subject><subject>Sensitivity and Specificity</subject><subject>Skin</subject><subject>Sputum - microbiology</subject><subject>T-Lymphocytes - immunology</subject><subject>T-Lymphocytes - metabolism</subject><subject>Time Factors</subject><subject>Tuberculin Test</subject><subject>Tuberculosis</subject><subject>Tuberculosis - diagnosis</subject><subject>Tuberculosis - epidemiology</subject><subject>Tuberculosis - immunology</subject><subject>Tuberculosis - microbiology</subject><issn>1549-1676</issn><issn>1549-1277</issn><issn>1549-1676</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2007</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><sourceid>BENPR</sourceid><sourceid>DOA</sourceid><recordid>eNqVk1-L1DAUxYso7rr6DUQLwoIPMyZp_vVFWJZVB0ZHnNXXkKRpJ0PbjEkq7rc341SdyjwofWhJfvecm5PeLHsKwRwWDL7ausH3sp3vOlPNAcAAluhedg4JLmeQMnr_6PssexTCFgBUghI8zM4gIxRjzs6z9dL1jY1DZZNWLkMwIXSmj7mrc9nnN8vF-uPqNo8mxLx2Pn9_p52SOhpvhy6PgzJeD60LNuS2r42O1vWPswe1bIN5Mr4vss9vbm6v382Wq7eL66vlTLMCx1lVmFoCUjKkSImBVKyqNMKQVIpDigutJC0kxhWBpjAIQW1KWBBYl0BKyoviInt-0N2lBsSYRxAQcQ5KxglPxOJAVE5uxc7bTvo74aQVPxecb4T00erWCKZqSqVKvrzCDCClMAGAElQDihjau70e3QaVItcpJC_bieh0p7cb0bhvAvLUNmRJ4HIU8O7rkAIVnQ3atK3sjRuCoBwSkI6ZwBd_gafPNjtQjUztp_BdctWN6U0yd72pbVq-gpSWnDNIEz8_waenMp3VJwteTgoSE8332MghBLFYf_oP9sO_s6svU_byiN0Y2cZNcO2w_83CFMQHUHsXgjf174uBQOzn5VeGYj8vYpyXVPbs-FL_FI0DUvwA7ZgPMA</recordid><startdate>20070601</startdate><enddate>20070601</enddate><creator>Hill, Philip C</creator><creator>Brookes, Roger H</creator><creator>Fox, Annette</creator><creator>Jackson-Sillah, Dolly</creator><creator>Jeffries, David J</creator><creator>Lugos, Moses D</creator><creator>Donkor, Simon A</creator><creator>Adetifa, Ifedayo M</creator><creator>de Jong, Bouke C</creator><creator>Aiken, Alex M</creator><creator>Adegbola, Richard A</creator><creator>McAdam, Keith P</creator><general>Public Library of Science</general><general>Public Library of Science (PLoS)</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>IOV</scope><scope>ISN</scope><scope>ISR</scope><scope>3V.</scope><scope>7TK</scope><scope>7X7</scope><scope>7XB</scope><scope>88E</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>M0S</scope><scope>M1P</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><scope>DOA</scope><scope>CZK</scope></search><sort><creationdate>20070601</creationdate><title>Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection</title><author>Hill, Philip C ; Brookes, Roger H ; Fox, Annette ; Jackson-Sillah, Dolly ; Jeffries, David J ; Lugos, Moses D ; Donkor, Simon A ; Adetifa, Ifedayo M ; de Jong, Bouke C ; Aiken, Alex M ; Adegbola, Richard A ; McAdam, Keith P</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c734t-d3efa05972b5940ab7ddc2415db81643cba63a44d51e3e221ce91351f90aa6833</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2007</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Aged</topic><topic>Antigens, Bacterial - immunology</topic><topic>Bacteria</topic><topic>Bacterial infections</topic><topic>Bacterial Proteins - immunology</topic><topic>Cohort Studies</topic><topic>Comparative analysis</topic><topic>Confidence intervals</topic><topic>Contact Tracing</topic><topic>Databases, Factual</topic><topic>DNA, Bacterial - genetics</topic><topic>Enzyme-Linked Immunosorbent Assay</topic><topic>Enzymes</topic><topic>False Negative Reactions</topic><topic>Female</topic><topic>Follow-Up Studies</topic><topic>Gambia - epidemiology</topic><topic>Genetic aspects</topic><topic>Humans</topic><topic>Immune system</topic><topic>Immunology</topic><topic>Immunology and allergy</topic><topic>Infections</topic><topic>Infectious Diseases</topic><topic>Interferon-gamma - analysis</topic><topic>Male</topic><topic>Medicine in Developing Countries</topic><topic>Middle Aged</topic><topic>Mycobacterium tuberculosis - immunology</topic><topic>Mycobacterium tuberculosis - isolation & purification</topic><topic>Predictive Value of Tests</topic><topic>Public Health</topic><topic>Public Health and Epidemiology</topic><topic>Reproducibility of Results</topic><topic>Respiratory Medicine</topic><topic>Sensitivity and Specificity</topic><topic>Skin</topic><topic>Sputum - microbiology</topic><topic>T-Lymphocytes - immunology</topic><topic>T-Lymphocytes - metabolism</topic><topic>Time Factors</topic><topic>Tuberculin Test</topic><topic>Tuberculosis</topic><topic>Tuberculosis - diagnosis</topic><topic>Tuberculosis - epidemiology</topic><topic>Tuberculosis - immunology</topic><topic>Tuberculosis - microbiology</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Hill, Philip C</creatorcontrib><creatorcontrib>Brookes, Roger H</creatorcontrib><creatorcontrib>Fox, Annette</creatorcontrib><creatorcontrib>Jackson-Sillah, Dolly</creatorcontrib><creatorcontrib>Jeffries, David J</creatorcontrib><creatorcontrib>Lugos, Moses D</creatorcontrib><creatorcontrib>Donkor, Simon A</creatorcontrib><creatorcontrib>Adetifa, Ifedayo M</creatorcontrib><creatorcontrib>de Jong, Bouke C</creatorcontrib><creatorcontrib>Aiken, Alex M</creatorcontrib><creatorcontrib>Adegbola, Richard A</creatorcontrib><creatorcontrib>McAdam, Keith P</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Gale In Context: Opposing Viewpoints</collection><collection>Gale In Context: Canada</collection><collection>Gale In Context: Science</collection><collection>ProQuest Central (Corporate)</collection><collection>Neurosciences Abstracts</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Medical Database (Alumni Edition)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Medical Database</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><collection>DOAJ Directory of Open Access Journals</collection><collection>PLoS Medicine</collection><jtitle>PLoS medicine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Hill, Philip C</au><au>Brookes, Roger H</au><au>Fox, Annette</au><au>Jackson-Sillah, Dolly</au><au>Jeffries, David J</au><au>Lugos, Moses D</au><au>Donkor, Simon A</au><au>Adetifa, Ifedayo M</au><au>de Jong, Bouke C</au><au>Aiken, Alex M</au><au>Adegbola, Richard A</au><au>McAdam, Keith P</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection</atitle><jtitle>PLoS medicine</jtitle><addtitle>PLoS Med</addtitle><date>2007-06-01</date><risdate>2007</risdate><volume>4</volume><issue>6</issue><spage>e192</spage><epage>e192</epage><pages>e192-e192</pages><issn>1549-1676</issn><issn>1549-1277</issn><eissn>1549-1676</eissn><abstract>Very little longitudinal information is available regarding the performance of T cell-based tests for Mycobacterium tuberculosis infection. To address this deficiency, we conducted a longitudinal assessment of the enzyme-linked immunosorbent spot test (ELISPOT) test in comparison to the standard tuberculin skin test (TST).
In tuberculosis (TB) contacts we repeated ELISPOT tests 3 mo (n = 341) and 18 mo (n = 210) after recruitment and TSTs at 18 mo (n = 130). We evaluated factors for association with conversion and reversion and investigated suspected cases of TB. Of 207 ELISPOT-negative contacts, 51 (24.6%) had 3-mo ELISPOT conversion, which was associated with a positive recruitment TST (odds ratio [OR] 2.2, 95% confidence interval [CI] 1.0-5.0, p = 0.048) and negatively associated with bacillus Calmette-Guérin (BCG) vaccination (OR 0.5, 95% CI 0.2-1.0, p = 0.06). Of 134 contacts, 54 (40.2%) underwent 3-mo ELISPOT reversion, which was less likely in those with a positive recruitment TST (OR 0.3, 95% CI 0.1-0.8, p = 0.014). Between 3 and 18 mo, 35/132 (26.5%) contacts underwent ELISPOT conversion and 28/78 (35.9%) underwent ELISPOT reversion. Of the 210 contacts with complete results, 73 (34.8%) were ELISPOT negative at all three time points; 36 (17.1%) were positive at all three time points. Between recruitment and 18 mo, 20 (27%) contacts had ELISPOT conversion; 37 (50%) had TST conversion, which was associated with a positive recruitment ELISPOT (OR 7.2, 95% CI 1.4-37.1, p = 0.019); 18 (32.7%) underwent ELISPOT reversion; and five (8.9%) underwent TST reversion. Results in 13 contacts diagnosed as having TB were mixed, but suggested higher TST sensitivity.
Both ELISPOT conversion and reversion occur after M. tuberculosis exposure. Rapid ELISPOT reversion may reflect M. tuberculosis clearance or transition into dormancy and may contribute to the relatively low reported ELISPOT conversion rate. Therefore, a negative ELISPOT test for M. tuberculosis infection should be interpreted with caution.</abstract><cop>United States</cop><pub>Public Library of Science</pub><pmid>17564487</pmid><doi>10.1371/journal.pmed.0040192</doi><tpages>10</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1549-1676 |
| ispartof | PLoS medicine, 2007-06, Vol.4 (6), p.e192-e192 |
| issn | 1549-1676 1549-1277 1549-1676 |
| language | eng |
| recordid | cdi_plos_journals_1288097858 |
| source | MEDLINE; DOAJ Directory of Open Access Journals; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central; Public Library of Science (PLoS) |
| subjects | Adolescent Adult Aged Antigens, Bacterial - immunology Bacteria Bacterial infections Bacterial Proteins - immunology Cohort Studies Comparative analysis Confidence intervals Contact Tracing Databases, Factual DNA, Bacterial - genetics Enzyme-Linked Immunosorbent Assay Enzymes False Negative Reactions Female Follow-Up Studies Gambia - epidemiology Genetic aspects Humans Immune system Immunology Immunology and allergy Infections Infectious Diseases Interferon-gamma - analysis Male Medicine in Developing Countries Middle Aged Mycobacterium tuberculosis - immunology Mycobacterium tuberculosis - isolation & purification Predictive Value of Tests Public Health Public Health and Epidemiology Reproducibility of Results Respiratory Medicine Sensitivity and Specificity Skin Sputum - microbiology T-Lymphocytes - immunology T-Lymphocytes - metabolism Time Factors Tuberculin Test Tuberculosis Tuberculosis - diagnosis Tuberculosis - epidemiology Tuberculosis - immunology Tuberculosis - microbiology |
| title | Longitudinal assessment of an ELISPOT test for Mycobacterium tuberculosis infection |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-08T07%3A52%3A10IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_plos_&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Longitudinal%20assessment%20of%20an%20ELISPOT%20test%20for%20Mycobacterium%20tuberculosis%20infection&rft.jtitle=PLoS%20medicine&rft.au=Hill,%20Philip%20C&rft.date=2007-06-01&rft.volume=4&rft.issue=6&rft.spage=e192&rft.epage=e192&rft.pages=e192-e192&rft.issn=1549-1676&rft.eissn=1549-1676&rft_id=info:doi/10.1371/journal.pmed.0040192&rft_dat=%3Cgale_plos_%3EA166988716%3C/gale_plos_%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1288097858&rft_id=info:pmid/17564487&rft_galeid=A166988716&rft_doaj_id=oai_doaj_org_article_7bf66ab6438d4702bb4500652f062723&rfr_iscdi=true |